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Parathyroid hormone secretion in chronic renal failure. The aim of
study was to introduce and evaluate a method for quantifying the
parathyroid hormone (PTH) secretion during hemodialysis in secondary
hyperparathyroidism due to end-stage renal failure. We developed a
method suable for inducing sequential hypocalcemia and hypercalcemia
during hemodialysis. During the development of the method we found
significantly different results of blood ionized calcium and serum PTH
Concentration when obtained from the arterial blood line on the dialysis
unit or from peripheral venous blood. However, when corrected for the
calculated recirculation of 3 to 25%, the result obtained from arterial
blood was comparable to the result from venous blood. Furthermore, the
results obtained from venous blood were comparable to the results of
sequential citrate and calcium clamping performed on a non-dialysis day.
From our data of venous blood during hemodialysis, blood PTH/ionized
calcium curves were constructed, and a mean calcium set-point of 1.16
mmol/liter was cstimated compared to the normal mean of about 1.13
mmol/liter. In conclusion, we demonstrate that it is important to use a
standardized method to evaluate parathyroid hormone dynamics in
chronic renal failure. By the use of a standardized method we show that
the calcium set-point is normal or slightly elevated, indicating normal
parathyroid reactivity to calcium in chronic renal failure.
Significant progress has been made in our understanding of the
regulation of the parathyroid hormone (PTH) secretion in vivo.
PTH is secreted in response to low extracellular ionized calcium
(Ca2) and acts on the bone and kidney to correct extracellular
Ca2, but the detailed mechanisms involved are not yet well
understood. The recent cloning of a calcium receptor in the
plasma membrane will probably bring new and important infor-
mation on the regulation of the PTH secretion.
In vivo investigations of the PTH secretion are needed to
evaluate the parathyroid secretory response to hypo- and hyper-
calcemia. The phenomenon of rate dependency and ability of the
parathyroid gland to sense the direction of changes in Ca2 makes
it important to evaluate the Ca2 /PTH relationship by the use of
standardized methodologies. At present there is conflicting evi-
dence from in vivo and in vitro studies concerning a shift in the
calcium set-point in uremia [1—51. This might be caused by the usc
of different in vivo methodologies for the evaluation of the
Ca2/PTH relationship in patients with chronic renal failure
(CRF). An in vitro study of Brown et al showed a great range of
calcium set-points [I]. The distribution of calcium set-points
varied from 0.6 mmol/liter to 1.6 mmol/liter in cell preparations
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from glands with secondary hyperplasia, even though the study
was conducted in a standardized manner [1]. The same difference
in the calcium set-point itt in vivo studies has been described by
others [2, 3], although the range of the set-points is narrower.
In a newly published in vivo study [2] the calcium set-point in
patients with secondary hyperparathyroidism (SHPT) due to CRF
was found to be normal compared to healthy controls, although
the basal levels of PTH were much higher than normal. In
contrast, Felsenfeld, Ross and Rodriques [3] found a higher
calcium set-point, a greater PTH maximal stimulation at basal
serum Ca2 (ratio of basal to maximal PTH) in patients with
osteitis fibrosa than in patients with low-turnover aluminium-
associated bone disease and aplastic bone disease. Whereas
Ramirez et al [21 and Felsenfeld et al [31 tried to estimate and
conclude upon the calcium set-point, Kwan et al [4] consequently
abstain from estimation of the calcium set-point in their elegant
studies. They argue that because they found the PTH!Ca2 curves
to be drawn under very different circumstances, the variations
could be caused by the difference in patient response to the
induction of hypo- and hypercalcemia [4]. At present some in vivo
studies dealing with in vivo PTH secretion in CRF have been
undertaken on two different days (1 day of stimulation, 1 day of
suppression) [2, 3], and only one study has been undertaken
during sequential induction of hypo- and hypercalcemia in one
session [4]. However, none of the studies listed have taken the
initial release of preformed PTH into account during their studies
of stimulation [2—4].
We have previously established a standardized method for
quantifying PTH secretion in vivo in normal humans, and in hypo-
and primary hypercalcemics based on sequential citrate and
calcium clamping [5—71. By the use of this standardized method,
we were able to describe the inverse sigmoidal relationship
between PTH and Ca2, measuring the maximal and minimal
PTH secretion and the calcium set-point.
The objective of the present study was: (1) to introduce and
evaluate a standardized method for quantifying PTH secretion,
based on sequential calcium lowering and raising during one
session of normal hemodialysis; and (2) to investigate the PTII
secretion by evaluation of the maximal and minimal PTH secre-
tion and the calcium set-point in patients with secondary hyper-
parathyroidism (SHPT) due to end-stage renal failure.
Methods
human volunteers
The study was performed with the approval of the ethical
committee of the University of Copenhagen (KF; 01-099/93).
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The study comprised 23 patients with SHPT due to end-stage
renal failure (11 females and 12 males) aged 33 to 77 years (mean
58 years) selected among the patients in chronic hcmodialysis
program at the Department of Nephrology, Hvidovre Hospital,
Copenhagen. All patients had a GFR below 5 mI/mm. The
patients had been on hemodialysis for 2 to 60 months (mean 26
months). None of the patients included in the study were treated
with calcium-based phosphate binders and/or vitamin D analogue.
Furthermore, none of the patients had, apart from uremia, any
known diseases affecting the calcium homeostasis.
Experiments
Protocol I served to establish a method (The Dia-clamp)
capable of inducing and maintaining sequential hypo- and hyper-
calcemia during hemodialysis. Protocol I comprised 11 patients (7
females and 4 males).
Protocol II was designed to (I) evaluate the Dia-clamp meth-
od's capability of inducing and maintaining sequential hypo- and
hypercalcemia; (2) elucidate PTH-secretion; and (3) compare the
Dia-clamp results obtained by the previously established method
of induced sequential hypo- and hypercalcemia taking place on a
non-dialysis day (the Cica-clamp [5]). Protocol II included 12
patients (4 females and 8 males).
Protocol III served to establish the reproducibility of the
Dia-clamp methods. Five patients (2 females and 3 males) from
protocol II participated.
Protocol I: Establishment of a Dia-clamp infusion profile
Based on our previously established Cica-clamp technique [51,
the aim was to establish four identical phases of hypo- and
hypercalcemia. In phase 1, blood ionized calcium (B-Ca2) was
lowered to 0.20 mmol/liter below the baseline within 30 minutes of
the start of infusion. Phase 2 held a steady state of B-Ca2 to
about 0.20 mmol/liter below baseline. In phase 3, B-Ca2 rose to
a concentration of 0.20 mmol/liter above baseline. Phase 4
maintained hypercalcemia at a steady state concentration of 0.20
mmol/liter above baseline.
During six trial investigations using only low calcium and high
calcium dialysate, inadequate hypo- and hypercalcemia was ob-
tained. During the next four trial investigations, infusion of
trisodium citrate followed by infusion of calcium chloride in
addition to low- and high-calcium dialysate was performed. This
model successfully established the four intended phases of hypo-
and hypercalcemia as described above.
Protocol II: Dia-clamp and Cica-clamp comparison
Based on our infusion profile of trial investigation 11 (protocol
I), we established our final Dia-clamp infusion model (Table 1).
The performance of the Dia-clamp was evaluated by: (1) the time
spent in achieving the B-Ca2 concentration of 0.20 mmol/liter
below baseline; (2) the method's ability to maintain the preset
steady state hypo- and hypercalcemia; and (3) the PTH response
obtained.
Protocol III: Reproducibility
The reproducibility of the established Dia-clamp model was
evaluated by performing a second Dia-clamp no more than one
week after the initial clamp. Performance of the reproducibility
was estimated by (1) the obtained hypo- and hypercalcemia during
the four phases, and (2) the PTH secretion obtained.
0—20 mm
Infusion of 0.20 mmol trisodium citrate kg' - body
wt hr
20—30 mm or until B-Ca2 0.20 mmol 1' below initial
concentration
Infusion of 0.14 mmol trisodium citrate kg -body
wt - hr1
30—90 or when B-Ca2 is 0.20 mmol 1' below initial
concentration
Infusion of 0.13 mmol calcium chloride kg -body
wt - hr
90—95 mm
Infusion pause
90—120 mm
Infusion of 0.17 mmol calcium chloride kg1 - body
wt hr'
120—150 mm or until B-Ca2 is 0.20 mmol liter above
the initial concentration
Infusion of 0.25 mmoi calcium kg - body wt - hr
150 or 180 when B-Ca2 is 0.20 mmol liter above initial
concentration
Infusion of 0.08 mmol calcium chloride kg' body
wt -
The Dia-clamp technique
After an overnight fast all the patients were hemodialyzed,
starting between 8 and 9 a.m. The patients were either placed in
a bed or were resting in a chair. All the patients were dialyzed on
either Gambro-500/600 or Gambro GFE 16/18 filters (Gambro,
Lund, Sweden). The dialysate flow rate was 500 mI/mm and the
blood flow rate was 200 to 300 mI/mm.
All hemodialyses were carried out initially against a calcium-
free dialysate [3605 mmol/liter sodium chloride, 70 mmol/liter
potassium chloride, 17.5 mmol/liter magnesium chloride and 105
mmol/liter aceto acetate per liter of concentrated dialysate (pH
1.5 to 3)] followed by a high calcium dialysate [3605 mmol/liter
sodium chloride, 70 mmol/liter potassium chloride, 17.5 mmol/
liter magnesium chloride, 105 mmol/liter aceto acetate and 61.25
mmol/liter calcium chloridehydrate per liter of concentrated
dialysate (pH 1.5 to 3)] [8]. Using a variable infusion rate
according to Table 1, trisodium citrate (300 mmol sodium and 100
mmol citrate per liter of water) or calcium chloride (60 mmol
calcium, 73 mmol sodium, and 193 mmol chloride per liter of
water) was added to the blood before entering the bloodstream.
The infusion rate was guided by frequent bedside determinations
of B-Ca2, aiming at a steady-state level of 0.20 mmol/liter below
the baseline concentration, within 30 minutes from the start of
infusion (phase 1). After 60 minutes of steady-state hypocalcemia
(phase 2) the B-Ca2 was increased (phase 3)10 a steady-state
level of B-Ca2 of 0.20 mmol/liter above baseline (phase 4).
The Cica-clamp
After an overnight fast all patients received a sequential
infusion of trisodium citrate followed by infusion of calcium
chloride according to the Cica-clamp formula, as described in
detail elsewhere [51. During phase 1, B-Ca2 was lowered about
Table 1. Final Dia-clamp model
Step I
Step 2
Step 3
Step 4
Step 5
Step 6
Step 7
Correction formula step 1—3:
actualB-Ca2 — targut
Actual infusion rate 125 11.112
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0.20 mmol/liter within 30 minutes and was maintained at this level.
Phase 2 maintained a steady state B-Ca2 of 0.20 mmol/liter
below baseline for 60 minutes. During phase 3, B-Ca2 rose to
about 0.20 mmol/liter above baseline, and finally, during phase 4,
B-Ca2 was maintained at its new steady-state level for 30
minutes.
Blood sampling and methods of analysis
During the Dia-clamp all blood samples were obtained from the
arterial blood line on the dialysis unit (Gambro AK 100; bicar-
bonate) (A), and from a canulla inserted in a cubital vein in the
opposite arm (V). During the Cica-clamp, blood samples were
obtained from a cubital vein contralateral to the fistula site.
During the Dia-clamp as well as the Cica-clamp determination of
B-Ca2 concentrations were performed at actual pH at 5 to 15
minute intervals. Blood samples for determinations of B-Ca2
concentrations were obtained under anaerobic conditions and
were analyzed immediately with a calcium selective electrode
(Ciba-Corning Ca2 °/pH Analyzer; Ciba Corning Diagnostics,
Essex, UK). For these blood samplings 1 ml syringes moistened
with calcium-titrated S4500 Heparin were used (Leo Pharmaceu-
tical Inc. and Radiometer, Denmark). Blood samples for mea-
surements of serum PTH were drawn at 5 to 15 minute intervals
(simultaneously to B-Ca2'), cooled on ice immediately, centrifu-
gated at +4°C and then stored at —18°C until analyzed.
Serum PTH was analyzed by a two-site immunoradiometric test
procedure with the two-site antibodies specific for the amino-
terminal 1-34 portion of the PTH molecule, the other for the
39-84 amino acid sequence (IncStar Corporation, Stillwater, MN,
USA) [9, 10]. Blood for measurements of electrolytes were taken
initially (time 0) and after 90 minutes and 180 minutes. Serum
albumin, serum protein, serum creatinine, serum sodium, serum
potassium, serum phosphate and serum magnesium were ana-
lyzed on an ECHTACHEM 750 (Johnson & Johnson, Rochester,
NY, USA). Curve fitting of corresponding B-Ca2 and serum
PTH values was performed using a commercial computer pro-
gram (Inplot 4.03 Graph PAD Software Inc., USA).
Normal reference values were, B-Ca2° 1.15 to 1.31 mmol
liter1 (mean 2 so) and serum PTH 1.1 to 4.8 pmol/liter
(range).
Statistics
The Wilcoxon matched pairs test and the Mann-Whitney U-test
was used for the statistical evaluation. Regression was performed
by using the least squares method. Only P < 0.05 at a two-tailed
test was considered statistically significant. Values are presented
as mean .sn unless indicated.
Results
Protocol I
Eleven trial investigations were performed in order to establish
the intended four phases of hypo- and hypercalcemia. During our
first six trial investigations we tried to reach the preset level of
hypo- and hypercalcemia by dialysis against a low- and high-
calcium dialysate. However, we found inadequate levels of hypo-
and hypercalcemia. During the following four trial investigations
we used side-infusion of trisodium citrate followed by infusion of
calcium chloride in addition to the low- and high-calcium dialy-
sate. The use of this protocol enabled us to obtain the four
Table 2. Clamp phases 2 to 4
Dia-clamp
(A)
Dia-clamp
(V) Cica-clamp
Baseline B-Ca2' 1.29 0.11 1.29 0.11 1.31 0.10
mmol/liter (mean SD)
Baseline serum calcium (total) 2.41 0.23 2.43 0.21 2.49 0.21
mmol/Iiter (mean SD)
Baseline serum magnesium 1.19 0.32 1.21 0.32 1.16 0.18
mmol/liter (mean SD)
Baseline serum phosphate 1.95 0.68 1.88 0.64 1.79 0.47
mmol/liter (mean SD)
Baseline serum PTH 17.0 15.3 14.0
pmol/liter (mean SD) (1.5—61.4) (1.4—51.6) (1.7—48.5)
Serum PTH, peak concentration 47.6 39.6 49.4
pmol/liter (mean, range) (2.0—149.0) (1.8—119.0) (2.3—162)
Serum PTH, max. secretion 39.1 34.5 24.7
pmol/liter (mean, range) (2.2—189.7) (1.9—161.6) (2.2—76.0)
Serum PTH, mm. secretion 5.6 5.1 5.5
pmol/Iiter (mean, range) (0.9—21.7) (1.0—18.1) (1.1—17.8)
Curve slope at PTH —7.3 —12.1 —14.8
midpoint (mean)
Calcium set-point 1.21 0.13 1.16 0.09 1.18 0.09
mmol/liter (mean SD)
intended phases of hypo- and hypercalcemia. Based on these four
trial investigations our final infusion formula was established
(Table 1). This formula was used throughout the rest of the study.
Protocol II
Table 2 shows the baseline values of B-Ca2, serum calcium
(total), serum magnesium, serum phosphate and serum PTH
(1-84) before the Dia-clamp (A and V) and the Cica-clamp in 12
patients. No statistical differences were observed between the
baseline values obtained just before the Dia-clamp and the
Cica-clamp.
Figure 1 shows the B-Ca2 and serum PTH (1-84) results
obtained during the Dia-clamp and Cica-clamp. During the first
10 minutes of phase 1 of the Dia-clamp we found a B-Ca2
lowering (A) of 0.25 mmol/liter to an average concentration
B-Ca2 of 1.04 mmol/Iiter compared to a lowering (V) of 0.10
mmol/liter to an average concentration of 1.19 0.09 mmol/liter
(P < 0.01). In comparison, during the Cica-clamp we observed a
B-Ca2 lowering, comparable to the (A) results of the Dia-clamp,
of about 0.22 mmol/liter to an average concentration of 1.09
0.10 mmol/liter. However, compared to the Dia-clamp results
there was a significant difference (P < 0.01). At the end of our
phase 1 the mean B-Ca2concentrations were 0.96 0.12 mmol/
liter (A) and 1.08 0.11 mmol/liter (V) versus 1.06 0.09
mmol/liter during the Cica-clamp (NS). The initial 10 minutes of
phase 1 in all cases showed a transient PTH release into the
bloodstream amounting to 47.6 pmol/litcr (A; range 2.0 to 149.0)
and 39.6 pmol/liter (V; range 1.8 to 119.0) versus 49.4 pmol!liter
(range 2.3 to 162.0) during the Dia-clamp and Cica-clamp,
respectively (NS; Table 2). During phase 2 the B-Ca2 concen-
trations were maintained at steady-state concentrations of 0.97
0.14 mmol/liter (A) and 1.05 0.11 mmol/liter (V) versus 1.04
0.09 mmol/liter, respectively (NS). During this phase 2, the serum
PTH concentrations declined to steady state concentrations of
39.1 (range 2.2 to 189.7) pmol/liter (A) and 34.5 (range 1.9 to
161.6) pmol/liter (V) versus 24.7 (range 2.2 to 76.0) pmol/liter,
Protocol III
The Dia-clamp (A) and (V) was reproducible as evaluated by
the obtained four phases of hypo- and hypercalcemia (P > 0.90).
Furthermore, no statistically significant difference was observed in
the PTH response, evaluated by the maximal and minimal PTH
secretion, the calcium set-point and the curve slope at PTH
midpoint (Table 4).
Side effects
During the Dia-clamp and the Cica-clamp, three of the patients
sensed a slight pain along the infusion cannula, and eight patients
sensed tingling of the lips and fingers. These symptoms appeared
and disappeared within the first 5 to 40 minutes of infusion.
Discussion
Precise testing of endocrine function demands carefully stan-
dardized stimulation and suppression. Our data show that it is
possible to establish a standardized method for sequential induc-
tion of hypo- and hypercalcemia suitably for quantiiing the
serum PTH (1-84) secretion during hemodialysis. However, there
were found conflicting results when measuring the B-Ca2 con-
centration during the Dia-clamp either from the incoming arterial
blood on the dialysis unit before entering the dialysis membrane
(A), or from a cannula inserted in a vein contralateral to the
fistula arm (V). On the one hand, the results obtained during
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A 0.9 to 21.7) pmol/liter and 5.1 (V; range 1.0 to 18.1) pmol/liter
versus 5.5 (range 1.1 to 17.8) pmol/liter, respectively (NS). During
the period of induced hypercalcemia serum phosphate remained
stable at a level of 1.28 0.45 mmol/liter during the Dia-clamp
(V) and 1.65 0.39 mmol/liter during the Cica-clamp. Further-
more, serum magnesium did not change significantly from the
values obtained during hypocalcemia.
When we compare the serum PTH (1-84) results obtained,
either by excluding or by including the results of the depot release
of preformed PTH (1-84) in the calculation, there were small but
significant differences. There was a significant change in the
average PTH maximum, but furthermore, significant changes in
the average calcium set-point and in the curve slope at PTH
midpoint were observed (Table 3). Figure 2 shows the B-Ca24/
serum PTH relationship obtained during phases 2 to 4 (after the
elimination of phase I results, the depot release). The calcium
set-point (the calcium concentration corresponding to half maxi-
mal inhibition of maximal PTH secretion) was 1.21 0.13
mmol/liter (A) and 1.16 0.09 mmol/liter (V) versus 1.18 0.09
mmol/liter during the Dia-clamp (A and V) and the Cica-clamp,
respectively (NS; Table 3). If we, as most authors have done,
include the depot release of PTH (1-84) into our fitting model,
then the calcium set-points are changed (Table 3). During the
Dia-clamp (A) a decrease of the calcium set-point was observed
(NS), during the Dia-clamp (V) an increase was observed (P <
0.02), and finally, during the Cica-clamp a decrease was observed
(P < 0.01). The curve slope at the PTH midpoint was normal or
slightly steeper in CRF patients compared to the curve slope
observed in normal humans undertaken by the Cica-clamp phases
2 to 4 [6]. The slope averaged —12.1 during the Dia-clamp (V)
and —14.8 during the Cica-clamp, respectively, compared to the
normal mean of —11.4 previously obtained in 22 normal humans
(NS) [6].
0 30 60 90 120 150 180
Time, minutes
Fig. 1. A. Blood ionized calcium (B-Ca2) concentrations (S, Cica-clamp,
mean total sD; venous Dia-clamp, mean total SD; and LI arterial
Dia-clamp, mean total SD) obtained during protocol 1/in 12 patients. B.
Serum parathyroid hormone (•, Cica-clamp, mean total se; U,venous
Dia-clamp, mean total suM; and , arterial Dia-clamp, mean total
SuM) obtained during protocol II in 12 patients.
respectively (NS). During the 90 minutes of induced hypocalce-
mia, serum phosphate declined significantly as expected from
1.88 0.64 mmol/liter to a final concentration of 1.15 0.47
mmol!liter (V) during the Dia-clamp (P < 0.005), and declined
significantly from 1.79 0.47 mmol/liter to a final concentration
of 1.64 0.42 mmol/liter (P < 0.01) during the Cica-clamp.
During the induced hypocaleemia, serum magnesium signifi-
cantly declined from 1.21 0.32 mmol/liter to a final concentra-
tion of 1.06 0.24 mmol/liter (V) during the Dia-clamp (P <
0.005), and remained unchanged at 1.16 0.18 mmol/liter during
the Cica-clamp (NS).
During phase 3 B-Ca2 increased from baseline by an average
of 0.42 0.18 mmol/liter (A) and 0.20 0.05 mmol/liter (V)
versus 0.22 0.06 mmol/liter during the Dia-clamp and Cica-
clamp, respectively. The level of hypercalcemia remained stable
throughout phase 4 in all cases. In accordance, the serum PTH
(1-84) concentration declined to average values of 5.6 (A; range
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Table 3. Serum PTH(1-84) results
Dia-clamp (A)
Phases 2-4
Dia-clamp (A)
Phases 1-4
Dia-Clamp (V)
Phases 2-4
Dia-clamp (V)
Phases 1-4
Cica-clamp
Phases 2-4
Cica-clamp
Phases 1-4
Maximal PTH Secretion 39.1 54.4 34.5 48.1 24.7 42.8
pmollliter (mean, range) (2.2—189.7) (2.4—184.2) (1.9—161.6) (2.2—165.1)' (2.2—76.0) (2.4_130)u
Minimal PTH Secretion 5.6 5.3 5.1 5.1 5.5 4.8
pmollliter (mean, range) (0.9—21.7) (0.8—19.6) (1.0—18.1) (1.0—18.8) (1.1—17.8) (1.1—16.5)
Curve slope at PTH midpoint (mean) —7.3 —10.7 —12.1 —14.8 75a
Calcium set-point mmol/liter (mean SD) 1.21 0.13 1.16 0.13 1.16 0.09 1.19 0.08a 1.18 0.09 1.15 0.09k'
a P < 0.02
0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0
B-Ionized calcium, mmol/Iiter
Fig. 2. Semm PTH (1-84) concentrations as a function of B-Ca2t Serum
PTH (S-PTH (1-84)) concentrations (•, Cica-clamp, mean total SEM;U,
venous Dia-clamp, mean total 5EM; and , arterial Dia-clamp, mean
total SEM) obtained during protocol 11 in 12 patients.
induced hypocalcemia showed significantly lower B-Ca2 concen-
trations (A) than (V), whereas, on the other hand, the (A)
concentrations measured were significantly higher during induced
hypercalcemia (Fig. IA). This observation, together with the fact
that the results obtained during Dia-clamp (V) were comparable
to the Cica-clamp results is of major interest since most prior
studies only measured the B-Ca2 concentrations during stimu-
lation and suppression tests using incoming blood in the dialysis
unit (A). Based on our results, this indicates that those other
studies might have obtained results of PTH (1-84) during a degree
of hypo- and hypercalcemia that was much less than intended.
Too low a degree of stimulation and suppression might have
influenced the results of the PTH maximum and minimum
secretion as well as the calcium set-point.
The observation of a significant difference between the B-Ca2
(A) and (V) concentration obtained during the Dia-clamp might
be caused by peripheral recirculation, as we have evidence for a
possible peripheral recirculation of 3 to 25% in some of our
patients investigated as judged by measurents of serum urea
according to the formula: r = (C — Ca)I(Cp — c) where C is the
concentration in peripheral blood, Ca is the concentration in the
incoming arterial blood and C is the concentration in the
returning blood (data not presented) [11, 121. If calculated
according to this formula, the (A) results corrected for periferal
recirculation was comparable to the (V) results. However, the
presence of cardiopulmonary recirculation may account for an
overestimation of the degree of peripheral recirculation [11, 12].
The serum PTH (1-84) results obtained during Dia-clamp (A
and V) and Cica-clamp showed a difference, although not signif-
icantly, and thereby the calculated calcium set-points were differ-
ent too. During the Dia-clamp investigations we observed a slower
initial and a greater variation of the preformed PTH (1-84)
release than during the Cica-clamp, which is in agreement with
the study of Kwan et al [41. However, by comparison of the area
under the PTH (1-84) curve (Fig. IB), no significant difference in
the total PTH (1-84) secretion (A and V vs. Cica-clamp) was
observed, which indicates that the difference in the rate of PTH
(1-84) release might be caused by the difference in the rate of
change of B-Ca2t This observation is in accordance to the
phenomenon of rate dependency in the control of PTH (1-84)
secretion by B-Ca2, as first documented by Grant et al [8] and
Schwarz et al [9, 10]. Based on how the PTH maximum was
calculated in this study, only small differences in the calculated
calcium set-points were found. The mean calcium set-points
varied between 1.16 mmol/liter and 1.21 mmol!liter, which is
slightly higher than the normal calcium set-point of 1.13 0.04
mmol/liter observed in a previous study by our group [5]. How-
ever, when the phase 1 results of the serum PTH release of
preformed hormone were calculated, the calcium set-points in-
creased if (A) was measured or decreased if (V) was measured
during the Dia-clamp or the Cica-clamp. This observation might
be explained by the difference of the concentration of preformed
intracellular depot PTH (1-84) obtained during the initial part of
phase 1 that estimated (A) and (V). Despite this discrepancy, we
still find the mean calcium set-points to be slightly higher than the
normal mean (range 1.15 mmol/liter to 1.19 mmol/liter) compared
to the normal mean of 1.13 mmol/liter [5, 61. These results are in
agreement with the observations of Ramirez et al [2] and Felsen-
feld et al [3], who found the calcium set-point to be normal or
slightly elevated in CRF. ihe in vitro study of Brown et al support
this observation too, as they determined the calcium set-point to
be normal or slightly elevated in glands of CRF patients compared
to normal parathyroid glands [1].
Another aspect of calcium sensing is the sensitivity of the
parathyroid glands to changes in Ca2, alterations expressed as
the slope of the sigmoidal curve (that is, the change in PTH that
will result from a given change in Ca2) [13]. In addition to our
observations of normal or slightly elevated calcium set-points,
there was a normal sensitivity of the parathyroid cells to Ca2 in
CRF as judged by the curve slope. The mean curve slope averaged
—12.1 during the Dia-clamp (V) and —14.8 during Cica-clamp
compared to the normal mean of —11.4. This observation indi-
cates the normal properties of the Ca2-sensing receptor and
normal intracellular mechanisms for PTH biosynthesis handling in
SHPT.
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Table 4. Clamp phases 2-4
Dia-clamp 1(A)
Phases 2-4
Dia-clamp 11(A)
Phases 2-4
Dia-ciamp I (V)
Phases 2-4
Dia-clamp 11(V)
Phases 2-4
Maximal PTH secretion 58.8 449 49.4 41.1
pmol/liter (mean, range) (13.6—189.7) (14.4—147.2) (12.9—161.6) (14.5—131.3)
Minimal PTH secretion 7.4 6.5 6.5 6.1
pmol/liter (mean, range)
Curve slope at PTH mid-point (mean)
(1.6—21.7)
—6.2
(2.0—17.3)
—9.9
(1.6—18.1)
—9.0
(2.0—17.2)
—17.3
Calcium set-point mmol/liter (mean SD) 1.24 0.19 1.24 0.14 1.19 0.11 1.18 0J4
In conclusion, we demonstrate that it is possible to establish a
standardized and reproducible method for evaluation of parathy-
roid hormone dynamics in CRF. Our data show that it is
important to highlight if blood samples were obtained from the
dialysis unit (A) or from a peripheral vein, as recirculation might
cause discrepancy in the results. We find the calcium set-point to
be normal or slightly elevated in CRF patients.
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